What Sets People Who Live to 110 Apart? The "Longevity Immune Cells" Found in Their Blood

"What differentiates those who live healthily to 100 years old from those who do not?"

A new clue has been found to the long-standing question pursued by longevity research.

The focus is not on diet, exercise habits, or special supplements, but on the "immune cells" flowing through our blood.

A research team from Osaka University and others closely examined the blood of people aged 100 and over, and even those over 110, and found that a special type of T cell, usually rare, becomes increasingly prominent with age.

This cell is called "CD4 cytotoxic T lymphocyte," abbreviated as CD4-CTL.

The research results revealed a slightly different picture from the conventional image that the immune system simply weakens with age.

In the bodies of those who live over 100 years, it is possible that the immune system is not just unilaterally declining due to aging, but is being "reorganized" to adapt to the threats encountered over many years.

"Those over 110 years old" are a special presence in longevity research

People over 100 years old are called "centenarians," and those over 110 are called "supercentenarians."

Supercentenarians are not just living long.

Among those who reach this age, there are people who avoid the onset of diseases like cardiovascular diseases and cancer, which generally increase with age, until very late in life.

For researchers, they are valuable models for understanding "how healthy human aging can be."

However, there is a major problem.

There are extremely few people who live to be over 110 years old.

Therefore, it is very difficult to conduct studies on the scale of thousands or tens of thousands, as is done with research on younger or typical elderly populations.

In this study, the total number of subjects was 28.

The breakdown was 8 people in their 70s to 90s, 10 people aged 100 to 109, and 10 people over 110.

While the numbers might seem like a small-scale study, considering the rarity of supercentenarians themselves, collecting blood from 10 people over 110 and analyzing their immune cells in detail is highly significant.

The special T cells that increased with age

The research team particularly focused on CD4-CTL.

In our bodies, numerous immune cells work to protect against bacteria, viruses, and abnormal cells.

Among them, T cells are central to immune responses.

Typical CD4 T cells are called "helper T cells" and play a role in instructing other immune cells and coordinating immune responses.

They are akin to commanders on a battlefield.

However, CD4-CTL is a bit different.

In addition to giving instructions, they have the ability to directly attack target cells themselves.

They approach infected or abnormal cells and use molecules to eliminate them.

Normally, this type of cell is not very abundant.

However, in this study, the proportion varied greatly by age group.

In those in their 70s to 90s, the median proportion of CD4-CTL among all T cells was about 4.0%.

For those aged 100 to 109, it was about 9.6%.

And for those over 110, it reached about 17.6%.

In simple comparison, those over 110 had more than four times the proportion of those in their 70s to 90s.

Considering that "immunity weakens with age," this is a seemingly puzzling phenomenon.

Of course, the entire immune function is not rejuvenating. The decline in immune function due to aging does occur.

However, it was suggested that some immune cells might actually increase and take on specific roles.

The cells were not just increasing but "cloning"

Even more intriguing was the mechanism by which CD4-CTL increased.

When the research team analyzed each cell in detail, they found that some CD4-CTLs were undergoing "clonal expansion."

Clonal expansion refers to the phenomenon where a single immune cell repeatedly divides to produce a large number of cells with the same characteristics.

When immune cells recognize a target, they increase the cells that can respond to that target.

For example, when encountering an infection, T cells that can recognize a specific virus proliferate, which is one example.

Thus, the fact that some CD4-CTLs were significantly increasing in people over 100 suggests it might not be mere coincidence but a result of fighting some antigen or abnormal cells over a long period.

This is where the researchers' important perspective lies.

Could it be that the aging of the immune system cannot be explained by a simple "decline in function"?

To cope with infections, inflammation, and abnormal cells repeatedly encountered over a long life, the immune system might be gradually changing its structure.

In other words, the immune system that has survived for 100 years might bear the "combat record" of the pathogens and abnormal cells it has encountered throughout that person's life.

The most attention-grabbing relationship with "cancer"

The reason this study garnered significant attention is the relationship between CD4-CTL and cancer.

The research team compared the sequences of receptors on proliferating T cells with those in public databases.

Each T cell has a "T cell receptor" that recognizes different targets.

If likened to a key and keyhole, each T cell has a key that fits a specific marker on the surface of a cell.

The analysis confirmed many matches between the T cell receptors of the study participants and the sequences in the database.

Upon examining 36 instances of actual clonal expansion in detail, 32 corresponded to data derived from T cells taken from patients with lung cancer, breast cancer, hepatocellular carcinoma, and others.

Reading just this, one might be tempted to make the provocative interpretation that "people over 100 are constantly fighting off cancer cells in their bodies."

However, the research results do not prove that far.

The important point is that no history of the corresponding cancers was confirmed in the research participants.

One possible hypothesis is that the immune system recognized and eliminated abnormal cells before they were clinically discovered as cancer.

In our bodies, abnormal cells are born daily due to DNA replication errors and other reasons.

Not all of these become cancer.

It is believed that many abnormal cells are eliminated by mechanisms like immune surveillance.

If the CD4-CTLs of supercentenarians strongly support this "immune surveillance," it could partially explain why they avoid major cancers until extreme old age.

However, this is still just a hypothesis at this stage.

Even if the receptor characteristics were similar to those of cancer patients' T cells, that alone cannot conclusively state that they were "attacking the same cancer antigens."

"Cause of longevity" or "result of longevity"?

There is a crucial point to consider when understanding this study.

Did they live long because they had many CD4-CTLs?

Or did they increase CD4-CTLs as a result of living healthily for over 100 years?

We do not know at this point.

This study is an observational study comparing people of different ages.

It is not a study that continuously tracked the same person at ages 50, 70, 90, 100, and 110 to observe how their immune cells changed.

Therefore, it cannot demonstrate a causal relationship that "increasing CD4-CTLs extends lifespan."

Moreover, the number of 28 people is too small to directly apply conclusions to the general population.

Interestingly, even among participants under 100, there were individuals with very high proportions of CD4-CTLs.

So, it is not necessarily a cell that "always increases at 100 years old."

Is it influenced by genetic factors?

Are past infections related?

Do lifestyle habits, gut bacteria, or chronic inflammation have an impact?

Or is it the result of a combination of multiple factors?

There are many points that need to be clarified in the future.

In fact, "special T cells of supercentenarians" were reported in 2019 as well

This discovery did not emerge entirely from scratch.

In 2019, the research group also reported that supercentenarians have a high number of CD4 T cells with cytotoxic abilities.

In that study, it was noted that CD4 T cells, which usually function as "immune commanders," transform into cells with direct attack capabilities and undergo clonal expansion in people over 110.

The 2026 study took it a step further, investigating "when they start to increase," "what characteristics they have," and "what they might target" in detail.

The finding that CD4-CTLs had already significantly increased by the age of 100 to 109 suggests that the reorganization of the immune system might become prominent around 100, rather than suddenly starting at 110.

On social media, voices ask, "Can't we test for it?"

After the research announcement, this result became a topic of discussion in overseas scientific communities and on social media.

A major point of discussion was the question, "Can't we find out if we have a lot of these cells while we're young?"

In Reddit's science community, questions like "If we measure the amount of CD4-CTLs while young, can we tell if we're the long-lived type?" were posted.

In response, another important question was raised in the discussion.

Did supercentenarians have many CD4-CTLs from a young age?

Or did their bodies increase them as needed after becoming elderly?

If it's the latter, measuring at 30 or 40 might not predict future lifespan.

This study alone does not provide that answer.

There is also hope that "increasing these cells could lead to longevity"

Another noticeable reaction on social media is the hope for therapeutic applications.

"Why not artificially increase these cells?"
"Could it be used for cancer prevention in the future?"
"Could it lead to immune cell therapy?"

Such reactions have been observed.

In longevity research, whenever a characteristic is found to be common among healthy elderly individuals, the idea of replicating it in younger people inevitably arises.

If CD4-CTLs truly play an important role in eliminating cancer cells or aging cells, artificially enhancing that function could potentially lead to new immunotherapies.

However, more immune cells are not always better.

Over-strengthening the immune system could lead to autoimmune reactions that attack normal tissues, so it's not as simple as "increasing cells that attack cancer leads to longevity."

Even if applied to treatment in the future, precise control over which cells to increase, to what extent, and when will be necessary.

"Being healthy is more important than living long"

On social media, there are voices not only of hope for the research itself but also expressing that "longevity and healthy lifespan are not the same."

In one discussion, based on the experience of a family member living close to 100 but developing dementia, opinions were shared that "simply living longer isn't necessarily desirable."

This is also a fundamental issue in longevity research.

Many researchers aim not just to extend the numerical lifespan to 120 or 130 years.

They aim to delay the onset of heart disease, cancer, dementia, frailty, and other conditions as much as possible, extending the period of independent living until the end of life, in other words, "healthy lifespan."

This is why supercentenarians are important research subjects.

Understanding the special mechanisms within their bodies could lead not only to technologies that "keep people alive until 110" but also to methods for "living healthier at 70, 80, and 90."

"Did they not get cancer because they had many cells," or "Did they have many cells because they didn't get cancer"?

Sharp questions about the causality of the research have also emerged on social media.

The idea is, "Since the elderly have lived a long time, they have encountered many abnormal cells, and as a result, immune cells capable of responding have increased."

This is also an important point that researchers need to verify